Nervous system: Astrocytic tumors

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA
Written2000-11Anne Marie Capodano
Laboratoire de Cytogénétique Oncologique, Hpital de la Timone, 264 rue Saint Pierre, 13005 Marseille, France

(Note : for Links provided by Atlas : click)

1. Identity

ICD-Morpho 9400/3 Astrocytoma, NOS
Atlas_Id 5007
Phylum Central Nervous system::Glioma
WHO/OMS Classification Central Nervous system

2. Classification

Note Astrocytic tumors comprise a wide range of neoplasms that differ in their location within the central nervous system (CNS), age and gender distribution, growth potential, extent of invasiveness, morphological features, tendency for progression and clinical course; there is increasing evidence that these differences reflect the type and sequence of genetic alterations acquired during the process of transformation.
    The following clinicopathological entities can be distinguished :
  • Pilocytic Astrocytomas (Grade I)
  • Fibrillary Astrocytomas (Grade II)
  • Anaplastic Astrocytomas (Grade III)
  • Glioblastoma Multiforme (Grade IV)
  • 3. Clinics and Pathology

  • gliomas have been observed following therapeutic irradiation.
  • familial clustering of gliomas is not uncommon: the association with defined inherited tumor syndrome incuding the Li-Fraumeni syndrome, Turcot syndrome, and the NF1 syndrome
  • Epidemiology diffuse astrocytomas are the most frequent intracranial neoplasm and account for more than 60% of all primary brain tumors; the incidence differs between regions, but there are 5 to 7 new cases per 100.000 population per year
    1. Pilocytic Astrocytomas / Grade I: pilocytic astrocytomas arise throughout the neuraxis and are common in children and in young adults; pilocytic tumors of the optic nerve cause loss of vision; pilocytic astrocytoma of the hypothalamus and third ventricular region primarily affect children; but tumors of the cerebral hemispheres generally occur in patients older than those with visual system or hypothalamic involvment
    2. Fibrillary Astrocytomas / Grade II: fibrillary astrocytomas arise in the cerebral hemisphere of young to middle-aged adults and the brain stem of children; occasional examples occur in the cerebellum or spinal cord; at any site these astrocytomas must be distinguished from pilocytic astrocytomas; all such tumors are pilocytic astrocytomas in the optic nerve whereas most are of the fibrillary type in the brain stem
    3. Anaplastic Astrocytomas / Grade III: anaplastic astrocytomas occur in the same locations as astrocytomas (I-II) and glioblastoma, but the majority affect the cerebral hemispheres; anaplastic astrocytomas generally occur in patients a decade older than those with better differenciated astrocytomas and a decade younger than those with glioblastomas
    4. Glioblastoma Multiforme / Grade IV: glioblastoma is by far the most common glioma; it affects principally the cerebral hemispheries in adults and the brain stem in children; but they are most frequent after the fifth decade; most glioblastomas are solitary but occasional examples are geographically separate in the same patient and warrant the designation multicentric ; usually, it appears as a central area of hypodensity surrounded by a ring of contrast enhanced and penumbra of cerebral oedema
      glioblastoma multiforme may develop de novo (primary glioblastoma) or though progression from low-grade or anaplastic astrocytoma (secondary glioblastoma); patients with a primary glioblastoma are usually older, present a rapid tumor progression and a poor prognosis; patient with secondary glioblastomas are younger and tumor progress more slowly, with a better prognosis; these two groups are histologically indistinguishable
    1. Pilocytic Astrocytomas / Grade I: this predominantly peadiatric brain tumor is a circumscribed astrocytoma composed in varying proportions of compacted and loose textured astrocytes associated with rosenthal fibers, eosinophilic granular bodies, or both; the lesion described is sometimes referred to as the juvenile pilocytic astrocytoma
    2. Fibrillary Astrocytomas / Grade II: this tumor is a well differanciated diffusely infiltrating neoplasm of fibrillary astrocytes
    3. Anaplastic Astrocytomas / Grade III: this tumor is an astrocytic tumor of fibrillary type which is intermediate in differenciation between the better differenciated astrocytoma and glioblastoma; it is an astrocytic neoplasm that typically exceeds well differenciated astrocytoma in terms of cellularity, nuclear pleomorphism and hyperchromasia necrosis of glioblastoma
    4. Glioblastoma Multiforme / Grade IV: this tumor is a highly malignant glioma most closely related to fibrillary or diffuse astrocytic neoplasms; glioblastomas are cellular masses with varied tissue patterns; it appears either infiltrating or discrete, with typical or atypical mitoses, endothelial vascular proliferation and necrosis

    another subgroup of glioblastoma can be distinguished: the giant cell glioblastomas; histologically it is a glioblastoma with giant cells (500 mm in diameter): it develops clinically de novo ; it is associated with a favorable prognosis
    Treatment treatment differs according to grade and location of tumor
    pilocytic astrocytomas can be cured by complete resection of tumor; if exeresis is not possible due to the location of the tumor, chemotherapy is indicated in young children and radiotherapy in adults
    in fibrillary astrocytomas, the treatment consists of total and extent resection of tumor
    in anaplastic tumors and glioblastoma multiforme, the treatment consists of total resection and radiotherapy and chemotherapy after surgery
    Prognosis in low grade astrocytomas, a correlation of proliferation was reported (Ki67 index) with clinical outcome; the proliferative potential correlates inversely with survival and time to recurrence; the mean survival time after surgery is 6-8 years in low-grade astrocytomas; after surgery, the prognosis depends on whether the neoplasm undergoes progression to a more malignant phenotype; in pilocytic astrocytomas, total cure is possible after total resection; in fibrillary astrocytomas reccurrence is frequent
    . in anaplastic astrocytomas and in glioblastomas, evaluation of the extent of resection can be a prognostic factor; prognosis is generally poor (about one year); patients below 45 yrs have a considerably better prognosis than elderly patients; primary glioblastomas have a short clinical history with a poor prognosis; survival is better in secondary glioblastomas

    4. Cytogenetics

  • In astrocytomas grade I, normal karyotype is observed most frequently; among the cases with abnormal karyotypes, the most frequent chromosomal abnormalityis loss of the X and Y sex- chromosomes; loss of 22q is found in 20-30% of astrocytomas; other abnormalities observed in low grade tumors include gains on chromosome 8q, 10p, and 12p, and losses on chromosomes 1p, 4q, 9p, 11p 16p, 18 and 19
  • In anaplastic astrocytomas, chromosome gains or losses are frequent: trisomy 7 (the most frequent), loss of chromosome 10, loss of chromosome 22, loss of 9p, 13q; other abnormalities, less frequently described are: gains of chromosomes 1q, 11q, 19, 20, and Xq
  • Glioblastomas show several chromosomal changes: by frequency order, gain of chromosome 7 (50-80% of glioblastomas), double minute chromosomes, total or partial monosomy for chromosome 10 (70% of tumors) associated with the later step in the progression of glioblastomas partial deletion of 9p is frequent (64% of tumors): 9pter-23; partial loss of 22q in 22q13 is frequently reported
    loss or deletion of chromosome 13, 13q14-q31 is found in some glioblastomas
    trisomy 19 was reported in glioblastomas by cytogenetic and comparative genomic hybridization (CGH) analysis; the loss of 19q in 19q13.2-qter was detected by loss of heterozigocity (LOH) studies in glioblastomas
    deletion of chromosome 4q, complete or partial gains of chromosome 20 has been described; gain or amplification of 12q14-q21 has been reported
    the loss of chromosome Y might be considered, when it occurs in addition to other clonal abnormalities
  • 5. Genes involved and Proteins

  • Alteration of genes involved in cell-cycle control:
    it is known that the progression of the-cell cycle is controled by positive and negative regulators; some autors report alteration in cell-cycle gene expression in human brain tumors
    the p16 gene and the p15 gene are located in 9p21, a chromosome region commonly deleted in astrocytomas; expression of p16 gene is frequently altered in these tumors: in 33-68% of primary glioblastomas and 25% of anaplastic astrocytomas
    the Rb gene located on13q chromosome plays an important role in the malignant progression of gliomas
    the p53 gene is a tumor suppressor gene located on chromosome 17p13.1; loss or mutation of p53 gene has been detected in many types of gliomas and represents an early genetic event in these tumors
    overexpression of MDM2 is also seen in primary glioblastomas
    others oncogenes have been found to be amplified in a few cases of astrocytomas : oncogenes Gli, MYC, MYCN, MET and N-Ras
  • Loss or inactivation of tumor suppressor genes:
    in addition to p53 gene, others tumor suppression genes play a role in astrocytomas
    loss of chromosome 10 is the most frequent abnormality associated with the progression of malignant astrocytic tumors; more than 70% of glioblastomas show LOH on chromosome 10; amplification of EGFR is always associated with loss of chromosome 10
    the PTEN gene located at the 10q23 locus is implicated more frequently in glioblastomas than in anaplastic astrocytomas
    another suppressor gene the MXII gene has also been located on the distal portion of chromosome 10 at the 10q24 at the 10q24-p25 locus
    homozygous deletion in the DMTB gene located on the region 10q25.3-26.1 have been reported in glioblastomas
    the LG11 novel gene located in 10p24 region is a suppressor gene rearranged in several glioblastomas tumors
    allelic loss of chromosome 22q wich contains the neurofibromatosis type 2, tumor suppressor gene NF2 is observed in 20-30% of astrocytomas. But another possibility is the involvement of another gene located on chromosome 22 in the tumorogenesis of astrocytomas
    most of these genes participate in the progression of astrocytomas (fig 1)
  • Expression of growth factors and growth factor receptors:
    the epidermal growth factor receptor (EGFR) coded by the EGFR cellular oncogene is located on human chromosome 7 at locus 7p12-p14; EGRF is amplified in 40-60% of glioblastomas; it constitues a hallmark: primary glioblastomas rarely contain EGFR overexpression; patients with anaplastic astrocytomas or glioblastomas have a poorer prognosis when EGFR gene amplification is present; amplification could be a significant prognostic factor in these tumors
    over expression of PDGFR-a (platelet derived growth factor) is asociated with loss of heterozygosity of chromosome 17p and p53 mutations in secondary glioblastomas
    others growth factors expressed in gliomas include fibroblast growth factors (FGFs), insulin-like growth factors (IGFs), and vascular endothelial growth factor (VEGF)
  • Molecular pathways in the progression of astrocytomas (from Ho-Keung and Paula Y.P. Lam)

    6. Bibliography

    Molecular analysis of genomic abnormalities in human gliomas.
    Bello MJ, de Campos JM, Kusak ME, Vaquero J, Sarasa JL, Pestaa A, Rey JA
    Cancer genetics and cytogenetics. 1994 ; 73 (2) : 122-129.
    PMID 8174086
    Gene amplification in malignant human gliomas: clinical and histopathologic aspects.
    Bigner SH, Burger PC, Wong AJ, Werner MH, Hamilton SR, Muhlbaier LH, Vogelstein B, Bigner DD
    Journal of neuropathology and experimental neurology. 1988 ; 47 (3) : 191-205.
    PMID 3367154
    Cytogenetics of human brain tumors.
    Bigner SH, Mark J, Bigner DD
    Cancer genetics and cytogenetics. 1990 ; 47 (2) : 141-154.
    PMID 2192793
    Pilocytc astrocytoma.In Pathology and Genetics of Tumors of the Nervous
    Burger PC, Scheithauer BW, Paulus W, Giannini C, Kleihues P
    A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors.
    Chernova OB, Somerville RP, Cowell JK
    Oncogene. 1998 ; 17 (22) : 2873-2881.
    PMID 9879993
    Gene amplification in human gliomas.
    Collins VP
    Glia. 1995 ; 15 (3) : 289-296.
    PMID 8586464
    Cytogenetic and molecular abnormalities in astrocytic gliomas (Review).
    Goussia AC, Agnantis NJ, Rao JS, Kyritsis AP
    Oncology reports. 2000 ; 7 (2) : 401-412.
    PMID 10671694
    Chromosome abnormalities in low-grade central nervous system tumors.
    Griffin CA, Long PP, Carson BS, Brem H
    Cancer genetics and cytogenetics. 1992 ; 60 (1) : 67-73.
    PMID 1591709
    PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.
    Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R
    Science (New York, N.Y.). 1997 ; 275 (5308) : 1943-1947.
    PMID 9072974
    MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
    Moulton T, Samara G, Chung WY, Yuan L, Desai R, Sisti M, Bruce J, Tycko B
    The American journal of pathology. 1995 ; 146 (3) : 613-619.
    PMID 7887443
    The molecular genetics of central nervous system tumors.
    Ng HK, Lam PY
    Pathology. 1998 ; 30 (2) : 196-202.
    PMID 9643506
    Investigation of genetic alterations associated with the grade of astrocytic tumor by comparative genomic hybridization.
    Nishizaki T, Ozaki S, Harada K, Ito H, Arai H, Beppu T, Sasaki K
    Genes, chromosomes & cancer. 1998 ; 21 (4) : 340-346.
    PMID 9559346
    PTEN gene mutations are seen in high-grade but not in low-grade gliomas.
    Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD, Bigner SH
    Cancer research. 1997 ; 57 (19) : 4187-4190.
    PMID 9331072
    Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval.
    Rosenberg JE, Lisle DK, Burwick JA, Ueki K, von Deimling A, Mohrenweiser HW, Louis DN
    Oncogene. 1996 ; 13 (11) : 2483-2485.
    PMID 8957092
    Detection of complex genetic alterations in human glioblastoma multiforme using comparative genomic hybridization.
    Schlegel J, Scherthan H, Arens N, Stumm G, Kiessling M
    Journal of neuropathology and experimental neurology. 1996 ; 55 (1) : 81-87.
    PMID 8558174
    EGFR gene amplification--rearrangement in human glioblastomas.
    Schwechheimer K, Huang S, Cavenee WK
    International journal of cancer. Journal international du cancer. 1995 ; 62 (2) : 145-148.
    PMID 7622287
    Molecular changes during the genesis of human gliomas.
    Sehgal A
    Seminars in surgical oncology. 1998 ; 14 (1) : 3-12.
    PMID 9407626
    Brain tumors. In : Cytogenetic Cancer Markers.
    Shapiro JR, Scheck AC
    Wolman SR and Sell S (eds). 1997.
    Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.
    Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV
    Nature genetics. 1997 ; 15 (4) : 356-362.
    PMID 9090379
    Karyotypes in 90 human gliomas.
    Thiel G, Losanowa T, Kintzel D, Nisch G, Martin H, Vorpahl K, Witkowski R
    Cancer genetics and cytogenetics. 1992 ; 58 (2) : 109-120.
    PMID 1551072
    Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization.
    Weber RG, Sabel M, Reifenberger J, Sommer C, Oberstrass J, Reifenberger G, Kiessling M, Cremer T
    Oncogene. 1996 ; 13 (5) : 983-994.
    PMID 8806688
    MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells.
    Wechsler DS, Shelly CA, Petroff CA, Dang CV
    Cancer research. 1997 ; 57 (21) : 4905-4912.
    PMID 9354456

    7. Citation

    This paper should be referenced as such :
    Capodano, AM
    Nervous system: Astrocytic tumors
    Atlas Genet Cytogenet Oncol Haematol. 2001;5(1):58-61.
    Free journal version : [ pdf ]   [ DOI ]
    On line version :

    8. External links

    arrayMap Topo ( C71,C72) arrayMap ((UZH-SIB Zurich)   [auto + random 100 samples .. if exist ]   [tabulated segments]
    Other databaseBrain Lower Grade Glioma (LGG) TCGA Copy Number Portal
    Other databaseGlioma (GBMLGG) TCGA Copy Number Portal
    Other databasePylocytic astrocytoma ( intOGen )
    Other databasePylocytic astrocytoma ( intOGen )
    Other databaseBrain Lower Grade Glioma [ Genomic Data Commons - NCI TCGA-LGG]
    Disease databaseNervous system: Astrocytic tumors
    REVIEW articlesautomatic search in PubMed
    Last year articlesautomatic search in PubMed

    © Atlas of Genetics and Cytogenetics in Oncology and Haematology
    indexed on : Wed Nov 28 16:25:45 CET 2018

    For comments and suggestions or contributions, please contact us